PLATFORM to Maximize Patient Knowledge of Health Goals After Acute

Status Completed

Clinical Trial Summary

The goals of this study are two fold: 1) To learn whether a personalized patient health goal and reminder tool helps patients to learn more about their condition and to make changes in behavior and medication taking to reduce the risk of another heart attack. 2) To examine a blood sample to learn how patients are responding to their medications. The study team will enroll approximately 220 patients in the hospital recovering from a heart attack. Half of the patients will receive the educational tools and a copy will be sent to their outpatient provider.

Clinical Trial Description

The goals of this study are two fold: 1) To evaluate the impact of a personalized patient health goal education and reminder tool on patient adherence to evidence based therapies and subsequent cardiovascular risk factor modification after acute myocardial infarction (AMI); 2) To assess age-related heterogeneity in antiplatelet response among AMI patients. This is a prospective study of ~220 AMI patients, with at least half over age 65 years. Patients will be surveyed with questionnaires (at baseline and 6 months post discharge) and biomarkers (baseline only) to assess the status of their physical function, depression, nutrition, inflammation, and response to antiplatelet therapies. Patients will also be administered a walking test and a grip strength test at baseline. About 1 week after hospital discharge, and again about 3 months after hospital discharge, about half of the patients and their outpatient providers will receive the personalized post-AMI health goal education and reminder tool on patient adherence to evidence-based secondary prevention therapies. Data will be analyzed in aggregate using descriptive statistics. The primary endpoint of interest is a composite measure of adherence at six months to secondary prevention therapies described as the sum of measures received divided by the sum of available opportunities. The secondary endpoint will be analyzed to describe platelet response profiles as a function of age. The study team anticipates the risks for this study to be minimal, since the patient does not receive any investigational therapies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01807208
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	March 2013
Completion date	January 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04451967` - Acute Myocardial Infarction Study in Northeastern China
Completed	`NCT05974397` - Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Not yet recruiting	`NCT04072081` - Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions	N/A
Recruiting	`NCT03940443` - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting	`NCT03707626` - Collateral Circulation to LAD and Wellens Sign
Completed	`NCT02669810` - EXCELLENT (EXpanded CELL ENdocardiac Transplantation)	Phase 2
Not yet recruiting	`NCT04104048` - Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
Active, not recruiting	`NCT02915107` - The SORT OUT IX STEMI OCT Trial	N/A
Completed	`NCT02896543` - The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction	N/A
Completed	`NCT02531165` - Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	N/A
Completed	`NCT02490969` - Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19	N/A
Withdrawn	`NCT01901471` - Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock	Phase 2
Completed	`NCT02312336` - A Pilot Study of Transcoronary Myocardial Cooling	N/A
Recruiting	`NCT02071342` - Study of ABSORB Stent in Acute Myocardial Infarction	N/A
Terminated	`NCT01972126` - MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction	N/A
Completed	`NCT02070913` - COOL-AMI EU Case Series Clinical Study
Completed	`NCT01216995` - Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)	Phase 2
Withdrawn	`NCT01678339` - Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients	N/A
Completed	`NCT01887080` - Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program	N/A
Completed	`NCT01627457` - Heart Cycle Prestudy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms